PIERRE FABRE Pharmaceuticals Starts New Phase IIA CLINICAL TRIAL for Schizophrenia Medication Candidate F17464

Pierre Fabre Pharmaceuticals announce the initiation of a Phase IIa clinical trial program for F17464, a new selective dopamine D3 receptor antagonist, in schizophrenia. The trial is designed to assess the efficacy and safety of F17464 compared to placebo in patients with acute schizophrenia. The six-week multinational European trial will enroll 142 patients.

This development is a reflection of Pierre Fabre Laboratories’ strategy to invest in R&D on priority franchises such as neuropsychiatry, oncology and dermatology.

About F17464: Pierre Fabre Pharmaceuticals laboratories’ candidate medication, F17464, is a potent oral selective D3 antagonist/5-HT1A partial agonist. It is currently being developed for the treatment of schizophrenia.

“After the marketing authorization issued in 2013 by the FDA to Forest Laboratories, Inc. now Actavis, plc for Fetzima® -levomilnacipran an active compound discovered by the Pierre Fabre Research Institute ; we welcome this new step with another molecule from our R&D experts’ research into the central nervous system. The originality of this new molecule and the initial pharmacodynamics and safety results are extremely encouraging,” declared Frédéric Duchesne, President of Pierre Fabre Pharmaceuticals.

Read the full story here:

Company Web Site:

http://www.pierre-fabre.com/en

2 Likes